Retained Rights and Limitations. Notwithstanding the exclusive license granted to RBNC in this Article 2 (License Grant), AMGEN retains a research-only right under AMGEN’s rights in and to the Licensed Patents, Joint Patents and Exclusively Licensed Know-How solely for AMGEN’s internal research use; provided, however, that neither AMGEN nor any of its Affiliates manufacture, clinically develop, interact with any Regulatory Authority with respect to, sell or otherwise commercialize, any Licensed Compound.
Retained Rights and Limitations. No rights to either Party’s Patents, Trademarks, Housemarks or other proprietary rights are granted pursuant to this Agreement except as expressly set forth herein, and all other rights are reserved. Notwithstanding the licenses granted in this Article 3 (Grant of License), each Party retains rights to perform (itself or through its Affiliates or contractors) its obligations under this Agreement and the Existing License Agreement.
Retained Rights and Limitations. Notwithstanding the licenses granted to BioAge in this Article 2 (License Grant), Amgen retains a research-only right under Amgen’s rights in and to the Licensed Patents solely for Amgen’s internal research use.
Retained Rights and Limitations. Notwithstanding the licenses granted to XXXXX in this Article 2 (License Grant), AMGEN retains (1) a research-only right under AMGEN’s rights in and to the Licensed Patents and Exclusively Licensed Know-How solely for AMGEN’s research use as tool molecules, but expressly excluding any right for AMGEN to use Licensed Compounds or Exclusively Licensed Know-How to [***], in each case for purposes of identifying therapeutic candidates, clinically develop, interact with any regulatory authority with respect to, or commercialize, any Licensed Compound or Program Compound; (2) all rights necessary for AMGEN (a) to continue collaboration with [***] in accordance with the Ongoing Studies Agreement, (b) to complete activities contemplated by the Ongoing Studies Agreement and (c) to collaborate with [***] to publish the results of the Ongoing Studies in accordance with Section 8.3; (3) all rights necessary for AMGEN to [***] and license [***] to conduct the Licensed Lead Antibody Compound manufacturing and related activities under the Order in accordance with Section 2.5.3; and (4) all rights necessary for AMGEN to [***] and license [***] to complete [***] in accordance with Section 2.5.3(j) and for AMGEN to conduct [***] as contemplated in Section 2.5.3(k).
Retained Rights and Limitations. The licenses under this Section 4 are subject to Wyeth's obligations described herein including payments by Wyeth as set forth in Section 5. For clarity, the license rights granted to Wyeth in this Section 4 specifically exclude the right *** or ***; or 3) to *** or *** without the use of Wyeth Confidential Information or Wyeth Materials. As consideration for the rights received in Section 4, Wyeth *** Wyeth ***. ***.
Retained Rights and Limitations. The licenses under this Section 4 are subject to GW's obligations described herein including payments by GW as set forth in Section 5. For clarity, the license rights granted to GW in this Section 4 specifically exclude the right 1) ***. Aurora retains the right to work with other parties on the same or similar targets, compounds, data and cell lines supplied by a Third Party or independently developed by Aurora without the use of GW Confidential Information, GW Compounds, or GW Materials. Except as expressly licensed herein, GW *** or *** under the Aurora Patents and Aurora Technology.
Retained Rights and Limitations. No rights to either Party’s patents, trademarks or other proprietary rights are granted pursuant to this Agreement except as expressly set forth herein, and all other rights are reserved. Subject to Section 2.3 (Development Prior to Option Exercise Date), Novartis shall not research, Develop, Manufacture, conduct Medical Affairs Activities with respect to or Commercialize Franchise Product 3 prior to the Option Exercise Date or any Licensed Product outside the Territory and Amgen shall not research, Develop, conduct Medical Affairs Activities with respect to or Commercialize any Licensed Product inside the Territory, in each case, other than as expressly set forth in this Agreement (including under a Development Plan). Notwithstanding the licenses granted in this Article 4 (Grant of License), each Party retains rights to perform (itself or through its Affiliates or contractors) its obligations under this Agreement.”
2.12 The proviso in the third to last sentence of Section 5.1 of the Agreement is hereby deleted in its entirety.
2.13 Section 5.4.5 of the Agreement is hereby deleted in its entirety.
2.14 Section 6.3 of the Agreement is hereby deleted in its entirety and replaced with the following:
Retained Rights and Limitations. No rights to either Party’s Patents or other proprietary rights are granted pursuant to this Agreement except as expressly set forth herein, and all other rights are reserved. For the avoidance of doubt, the license granted in Section 3.1 (License to Rani) does not restrict Celltrion from supplying and commercializing Drug for any product that is not Product.
Retained Rights and Limitations. No rights are granted to Licensee hereunder to Licensed Technology outside the Licensee Indications or outside the Territory. No rights are granted to Licensee hereunder to import the Licensed Product from any Third Party other than from Licensor or its designee. No rights to either Party’s patents, trademarks or other proprietary rights are granted pursuant to this Agreement, except as expressly set forth herein, and all other rights are reserved.
Retained Rights and Limitations. Except as expressly granted in this Article 3, no rights are granted to Licensee hereunder to Licensed Amgen Patents, Licensed Amgen Know-How or Licensed Amgen Trademarks outside the Indications, or outside the Licensee Territory. Except to the extent expressly set forth in Sections 7.2 (Clinical Supply) or 7.3 (Commercial Supply), no rights are granted to Licensee hereunder to make or have made a Licensed Product or any other product. No rights are granted to Licensee hereunder to import or export a Licensed Product manufactured by Amgen or its licensee, except as specifically contemplated herein. No rights are granted herein to Licensee to control the research, development or commercialization of a Licensed Product in the Amgen Territory except, with respect to development, as otherwise agreed by the Parties through the Development Committee and, with respect to commercialization, as allowed under Section 5.5 (Co-Promotion Rights). No rights to either Party’s patents, trademarks or other intellectual property or proprietary rights are granted pursuant to this Agreement except as expressly set forth herein, and all other rights are reserved.
